Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by canadapieton Feb 09, 2020 11:52am
82 Views
Post# 30664099

RE:RE:RE:RE:Back to the MGH/DrG announcement

RE:RE:RE:RE:Back to the MGH/DrG announcementHi all, 

i read that latest pr as a positive, but reading others opinions and
interpretations makes one confused. And honestly, they let the door open 
for doubt!
So i try to talk to mr. T. next week asking for some clarifications!

Phase 3? Grinspoon ? Money (shelf offering)? I R person?
But hey, we are where we are and what importance has 1 month or
3 months ..........

The greatest disappointment is they won't make it with their 2 approved 
products, which i thought they would have a market cap way over 1 B!!!!

Greets






SPCEO1
 - (2/9/2020 10:53:06 AM) 
RE:RE:RE:Back to the MGH/DrG announcement
Occam's Razor - the simplest explanation is the most likely to be correct. Luc told Canadapiet the type C meeting already took place. Grinspoon's Lancet article makes a sensible case for a phase III. The company just announced a formal agreement with Grinspoon and MGH. They plan to hire an investor relations person. They filed a shelf offering. The company talks straightforwardly about starting a phase III later this year. It would be hard for me to make a case based on the info we have that the phase III is not a go. It is now just a question of what it is going to look like.

I believe Palin and your concerns are way overblown. TH really needs help in getting their communications with the market fixed but theya re giving us enough to know that there is a very high chance of a phase III starting later this year (or maybe early 2021 given the normal delays).

If they were not moving forward, they certainly would not need an IR person as the story is much more bland without HIV NAFLD/NASH on the horizon. 

But they have not yet hired the IR person so there is still a little room for doubters to doubt. It could be argued that they are not going to hire that IR person until they know for sure that the phase III protocol, with whatever adjustments the FDA and EMA may be asking for, has been approved by the board of directors. But I think the Grinspoon/MGH press release is almost as a good a "tell" as hiring the IR person. 
Bullboard Posts